Latanoprost Versus Fotil

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pharmaceutical Research Network
• Treatments: Latanoprost

Criteria

Inclusion Criteria:

• adults with primary open-angle or pigment dispersion glaucoma, or ocular hypertension

• untreated intraocular pressure should be between 24-36 mm Hg inclusive

• visual acuity should be 5/50 or better in both eyes

Exclusion Criteria:

• presence of exfoliation syndrome or exfoliation glaucoma

• contraindications to study medications

• any anticipated change in systemic hypotensive therapy